I am pleased to present a guest post from Dr. Sandro Santagata
of Brigham and Women’s Hospital/Dana Farber Cancer Center, who writes:
Our group of collaborators has recently
opened a Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
that is sponsored by the Alliance for Clinical Trials in Oncology.
The
eligibility criteria are listed here: https://clinicaltrials.gov/ct2/show/NCT03224767
The trial is
based on work published in these two papers:
I am happy to
answer any questions that our colleagues may have about this trial. ssantagata@bics.bwh.harvard.edu
No comments:
Post a Comment